home · filing · 0001829126-25-000818
8-K filed February 10, 2025, 6:59 PM ET
ticker ZEOX
CIK 0001557376
M&A
confidence high
sentiment positive
materiality 0.55
Zeo ScientifiX enters joint development MOU with BioXtek, appoints Dr. Peter Everts as CSO
Zeo ScientifiX, Inc.
Binding MOU with BioXtek for joint development, manufacturing, marketing, and funding arrangement.
ZEO to relocate to BioXtek's 11,000 sq ft Pompano Beach facility by May 31, 2025.
Parties to form 50/50 SPE to pursue FDA BLA approval for membrane products.
Dr. Peter Everts appointed CSO; salary $220K first year, option for 25,000 shares at $3.05.
Severance: 1/4 month salary per 3 months after 90-day initial period.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2025-02-07
Filed February 10, 2025, 6:59 PM ET
Effective February 7, 2025, Dr. Peter A. M. Everts, Ph.D. (“ Dr. Everts” ) was appointed the Company’s Chief Scientific and Technology Officer.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Peter A. M. Everts was appointed as Chief Scientific and Technology Officer at Zeo ScientifiX, Inc..
Action appointed
Role Chief Scientific and Technology Officer
Exact text from the filing
Effective February 7, 2025, Dr. Peter A. M. Everts, Ph.D. (“ Dr. Everts” ) was appointed the Company’s Chief Scientific and Technology Officer.
View on SEC.gov
Source: SEC EDGAR
accession 0001829126-25-000818
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.